NCT07459686Active, not recruiting
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
VELSIPITY® TABLETS 2 MG SPECIAL INVESTIGATION (INVESTIGATION ON LONG-TERM USE IN PATIENTS WITH ULCERATIVE COLITIS)
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1 (actual)
- First submitted
- 5 Mar 2026
- Start date
- 27 Apr 2026
- Primary completion date
- 29 Jan 2029
- Lead sponsor
- Pfizer
- Diseases
- Ulcerative colitis
- NCT number
- NCT07459686
What you commit to
- Study type: Observational
- Participants enrolled: 1
- From 27 Apr 2026 to the primary completion date, 29 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:
- Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded.
- Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.
Age in the registry: 0 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pfizer Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.